Melva

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Melva

Quick Facts

Property Description
Active ingredient Meloxicam
Form Tablets, Ampoules, Suspension, Suppositories
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Symptomatic relief of pain and inflammation
Origin Synthetic compound (Oxicam derivative)

What Type of Medicine Is Melva (Meloxicam)?

Melva is a medicinal product containing the active substance Meloxicam, which is chemically defined as an oxicam derivative. It is a prescription-only medicine (Rx) that belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class, a category clinically recognized for its systemic effects against inflammation. Meloxicam is recognized for its efficacy in managing inflammatory processes. Its classification as an NSAID establishes its primary use in providing symptomatic relief for adults experiencing chronic inflammatory conditions.

Composition, Origin, and Available Forms

Melva is derived from the single active ingredient, Meloxicam, which is a synthetic compound that is not derived from natural sources. Meloxicam is supplied in several forms to suit different clinical needs, including oral options such as tablets and capsules, a liquid oral suspension, and specialized preparations like injectable solutions (ampoules) and suppositories. The availability of both oral and parenteral forms is a key feature, allowing the medicine to be delivered via the oral, rectal, or parenteral (intramuscular) routes, depending on the required speed and method of absorption.

General Purpose and Anti-inflammatory Action

The primary purpose of Melva is to deliver anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) effects throughout the body. Its core benefit is providing symptomatic relief from the discomfort and swelling associated with inflammatory conditions. This action is achieved through the preferential inhibition of the Cyclooxygenase-2 (COX-2) enzyme, reducing the production of pro-inflammatory messengers called prostaglandins. The mechanism of Meloxicam is focused on reducing the biological signals that initiate pain and swelling. The medication is designed to block the body's pain and inflammation pathways.

Regulatory References

  1. NSAID Toxicity (NIH/NCBI)

What side effects are possible with Melva?

Possible Side Effects and Safety Information

Melva's officially documented safety profile centers on specific and serious adverse reactions as determined by regulatory authorities (such as the FDA, EMA).

Adverse Reactions and Toxicity

The most frequently documented side effects are related to Hematologic Toxicities (effects on blood cell counts), which are classified as Very Common (occurring in 10% or more of patients) and require mandatory monitoring and potential dose modification:

  • Decreased blood cell counts, including platelets (Thrombocytopenia), neutrophils (Neutropenia), lymphocytes, and hemoglobin (Anemia).
  • Non-hematologic very common reactions include fatigue, nausea, diarrhea, vomiting, pyrexia (fever), and respiratory tract infections.

Serious Adverse Reactions (SARs) documented in regulatory information include major infections (such as pneumonia and sepsis), severe bleeding events, and the long-term risk of developing Second Primary Malignancies. Patients are strictly monitored for these events during treatment.

Safety Restrictions and Population Considerations

The medicine's regulatory status is defined by a critical safety finding: an observed detrimental effect on Overall Survival (increased risk of death) in a specific patient population, particularly those who have had an autologous stem cell transplant (ASCT) and whose disease progressed within a certain period. This finding led to significant regulatory actions, including the withdrawal of accelerated approval in some regions, and it restricts the use of the medicine to defined patient subsets based on prior treatment history. The official regulatory notes emphasize that continuous monitoring of blood counts and signs of infection is mandatory throughout treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documents mandate that an individual seek immediate medical attention and contact emergency medical services or a poison control center if a Melva (Meloxicam) overdose is suspected. This immediate action is required due to the potential for severe, life-threatening outcomes documented in official labeling.

Overdose manifestations typically reflect the effects of Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Classification Documented Regulatory Statements
Common Manifestations Lethargy, drowsiness, nausea, vomiting, and epigastric pain (upper abdominal discomfort).
Severe Outcomes Gastrointestinal bleeding, acute renal failure, hypertension, coma, convulsions (seizures), cardiac arrest, and respiratory depression.
Antidote Availability No specific antidote is known for Meloxicam overdosage.

Management of overdosage must rely strictly on symptomatic and supportive treatment, as directed by regulatory authorities. Procedures such as gastric decontamination (e.g., gastric lavage) and the administration of activated charcoal are described as potential measures to reduce drug absorption if performed shortly after ingestion. Hospital monitoring and intensive medical care may be necessary, particularly when severe complications arise.

Therapeutic Uses of Melva

Melva is used to help manage and relieve symptoms associated with certain common conditions. Its application is based on its ability to assist in reducing discomfort in various clinical scenarios.

Melva is typically considered for supporting the management of mild to moderate pain, fever, and inflammation. Common clinical uses include addressing temporary discomfort from conditions such as headache, muscle aches, and symptoms related to the common cold or flu. The primary goal of use is supportive symptom management, which may help the patient feel more comfortable during recovery.

“Melva is a useful option for managing temporary discomfort.”


Quick Fact: Supportive Relief for Discomfort Melva may provide temporary relief for common aches and discomforts, supporting patient comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus drug information

Eligibility and Restrictions for Use

Who Can and Cannot Use Melva?

The population eligibility for Melva (Meloxicam) is strictly defined by regulatory authorities based on age, specific health conditions, and organ function.

Populations For Whom Use Is Contraindicated

Melva is absolutely contraindicated (must not be used) in patients with the following conditions, according to official labeling:

  • Known hypersensitivity or allergic reactions (e.g., asthma, hives) to meloxicam, aspirin, or any other nonsteroidal anti-inflammatory drug (NSAID).
  • Use for pain management in the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Active or history of recurrent gastrointestinal ulceration/bleeding.
  • Severe renal impairment who are not on dialysis, or severely impaired liver function.

Age-Related and Conditional Eligibility

Population Category Official Regulatory Status
Pediatric Patients Contraindicated in children under 16 years of age for general use (EU/UK). Approved for Juvenile Rheumatoid Arthritis in patients 2 years of age and older (US).
Pregnancy Contraindicated in the third trimester (at or after 30 weeks gestation). Use must be avoided from 20 weeks onward.
Renal Impairment Restricted in patients on hemodialysis, requiring a lower maximum daily dose.
Older Adults Use requires caution due to a higher risk of gastrointestinal, cardiac, and renal adverse events, often necessitating a lower starting dose for chronic treatment.

Eligibility is also restricted for patients with severe heart failure or volume depletion (hypovolemia), which must be corrected prior to use.

What should I know about interactions with other medicines?

The official regulatory interaction profile for Melva details effects on hemostasis, renal function, and the clearance of co-administered medicines, structured around Additive Pharmacodynamic Risks and Altered Systemic Exposure outcomes.

The use of Melva is contraindicated for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or analgesic doses of aspirin is not generally recommended due to the significantly increased risk of serious gastrointestinal adverse events.

Clinically significant interactions are documented with substances that affect blood clotting. Co-use with anticoagulants (such as Warfarin), antiplatelet agents, and certain antidepressants (SSRIs/SNRIs) is associated with an increased risk of bleeding. Additionally, Melva may diminish the antihypertensive effects of ACE Inhibitors, ARBs, and Beta-Blockers, and the natriuretic effects of Diuretics. This combination also carries a population-specific risk of renal function deterioration in elderly, volume-depleted, or renal-impaired patients.

Melva is documented to increase the plasma levels of Lithium, Methotrexate, and Cyclosporine, which raises the risk of toxicity from these agents. Finally, a formulation-specific constraint restricts the concomitant administration of Melva oral suspension with Sodium Polystyrene Sulfonate.

Mechanism of Action

Melva is designed to exert a targeted influence on core regulatory systems by engaging specific biological mechanisms within the body. Its action is focused strictly on modulating activity within specific biological pathways.

Targeted Modulation of Key Receptor Systems

Melva initiates its effect by acting on defined biological targets, such as specific receptor subtypes or regulatory enzymes, which are critical components of cellular communication. This focused interaction is used to initiate or block molecular signaling events, resulting in the regulation of processes driven by distinct signaling patterns.

Interfering with Signal Transduction Cascades

Following its primary binding, Melva modifies early molecular steps within well-characterized signal transduction cascades. By intervening in these sequences, the drug alters signaling dynamics in defined neural or humoral pathways. This mechanistic interference is relevant in systems where targeted pathway adjustment results in changes to systemic physiological function.

Altering Physiological Pathway Activity

The mechanism of Melva ultimately aims to result in a shift toward a modified state within targeted pathways. By influencing core mechanisms underlying the action, Melva alters activity within physiological pathways and reduces the concentration or binding of specific mediators, leading to physiological adjustments.

Dosage and Administration Information

How to Use Melva

This section outlines the usage instructions for Melva (meloxicam), defining the administration standards and dosage patterns standard for this medication.


Administration and Dosing Principles

Melva is supplied in forms for both oral and intravenous (IV) administration. Oral forms include tablets, capsules, and a suspension, while the IV injectable solution is used for specific pain management.

Common practice is to administer the medicine at the lowest effective dose for the shortest duration necessary. For most adult indications, the typical oral dose is 7.5 mg or 15 mg, and the dose is taken once daily (qDay). The IV injection is typically dosed at 30 mg once daily.


Context of Intake and Special Conditions

Oral formulations may be taken with or without food, although recommendations include taking the dose during a meal with water. The IV solution is administered by a healthcare professional as an intravenous bolus injection over 15 seconds, and the patient must be well hydrated prior to administration.

For certain patient populations, such as those with end-stage renal disease on hemodialysis, the maximum daily oral dose is restricted to 7.5 mg for tablets or 5 mg for capsules. Additionally, due to differing systemic exposure, the various oral formulations (tablets versus capsules) are not considered interchangeable on a milligram-for-milligram basis. If a dose is missed, it is typically taken as soon as possible, but the dose is skipped entirely if the next scheduled dose is almost due, to prevent doubling the amount.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Melva

Evidence for Use in Osteoarthritis

The research record indicates Meloxicam was evaluated in randomized controlled trials (RCTs) involving adults with confirmed osteoarthritis of the hip or knee. These studies focused on measuring patient-reported outcomes describing perceived discomfort and monitoring changes in daily functioning, such as stiffness and activity level, over periods often lasting several weeks to a few months. Some comparative research explored how these outcomes were tracked against other standard non-steroidal anti-inflammatory drugs (NSAIDs).


Evidence for Use in Rheumatoid Arthritis

For chronic conditions like Rheumatoid Arthritis, the evidence base shows Meloxicam was studied in medium-term clinical trials. Researchers utilized established measures like the ACR criteria and global patient assessments to track outcomes related to systemic or functional imbalance. Studies monitored how these measures evolved in the observed populations, typically over periods ranging from three to twelve months.


Evidence for Use in Acute Pain

Recent clinical research includes trials assessing formulations of Meloxicam for the management of moderate-to-severe pain in adults, often in a post-surgical setting. These acute studies primarily focused on measuring immediate changes in pain intensity over short observation periods. Data show patterns related to how physical discomfort was measured during these timeframes.


Research in Special Populations

Clinical research shows Meloxicam was studied for Juvenile Idiopathic Arthritis (JIA) in pediatric populations aged two years and older. Comparative trials monitored outcomes related to disease activity over a one-year treatment period. While studies reported comparable patterns in symptomatic tracking in this age group, the data for certain groups remain insufficient compared to the extensive adult research.


Long-Term Research and Study Duration

The key registrational studies for chronic conditions were primarily short- to medium-term. Follow-up durations were limited in many pivotal trials. Research describes that long-term effects are not fully established regarding the maintenance of functional outcomes over many years, and the evidence quality varies across studies when examining these long-term outcomes.

Frequently Asked Questions (FAQ)

Common questions about Melva (FAQ)


Q: How long does it typically take to start feeling the effects of Melva?

Studies on the way the body processes Melva indicate that stable levels of the medicine are typically reached within three to five days of beginning treatment. This period is often when stable drug levels are reached, which supports the medicine's consistent effect.


Q: What happens if I miss a day of taking Melva?

Regulatory guidance on missed doses advises taking the dose as soon as it is remembered. However, if the time for the next scheduled dose is approaching, regulatory guidance suggests skipping the dose entirely to prevent taking a double amount.


Q: How is Melva different from older medications for the same condition?

Melva is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) with a mechanism of action involving the preferential inhibition of the COX-2 enzyme over COX-1. This preferential action is used by the medicine to reduce inflammatory messengers that cause pain and swelling.


Q: What is the longest someone has been on Melva according to studies?

Clinical trials examining long-term effects, such as cardiovascular risks, have been conducted for durations of up to three years. However, official regulatory notes emphasize that long-term effects are not fully established regarding the maintenance of functional outcomes over many years of use.


Q: Does Melva affect the results of any common lab tests?

Official labeling requires patient monitoring for specific adverse reactions, including effects on the blood, liver, and kidneys. This monitoring involves specific laboratory tests, such as those that track blood cell counts and organ function markers.


Q: Can Melva be crushed or split if it's hard to swallow?

Regulatory product information states that certain oral formulations, such as orally disintegrating tablets, official instructions state that they should not be cut, crushed, or chewed. Furthermore, official sources indicate that the various oral formulations are not considered interchangeable on a milligram-for-milligram basis.


Q: Is Melva a controlled substance or addictive?

Melva (Meloxicam) is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not listed as a controlled substance by US authorities and is not considered a narcotic. It does not possess properties associated with physical dependence.


Q: Why do some people say Melva didn't work for them?

Studies have evaluated the medicine’s effectiveness in groups of patients with inflammatory conditions. However, the official information acknowledges that individual responses can vary depending on factors like medical history and the severity of the condition being treated. As with all prescription medicines, the effectiveness can differ from person to person.


Q: Is it common to feel tired when first starting Melva?

In clinical trials, fatigue was documented as a Very Common side effect, meaning it was reported by 10% or more of patients. This is one of the non-hematologic side effects observed in the safety profile.


Q: Can Melva cause weight changes (gain or loss)?

Regulatory documents note the potential for the adverse event of fluid retention and edema (swelling). Fluid retention is a condition that may sometimes lead to an unexplained gain in body weight.


Q: Can Melva affect mood or cause anxiety?

Official drug labels list certain central nervous system (CNS) effects, such as dizziness and drowsiness, as documented side effects. These effects may indirectly impact how a person feels.


Q: Does Melva have a 'half-life' and what does that mean?

The half-life is a pharmacokinetic term referring to the time it takes for the amount of medicine in the body to decrease by half. Melva has an elimination half-life of approximately 15 to 20 hours. This property supports its typical dosing schedule of once daily.


Q: What kind of specialist usually prescribes Melva?

Melva is officially indicated for the management of conditions such as Osteoarthritis, Rheumatoid Arthritis, and Juvenile Idiopathic Arthritis. Because of these indications, the medicine is commonly prescribed by specialists who focus on musculoskeletal and inflammatory diseases, such as rheumatologists.


Q: Are there any long-term effects of taking Melva for many years?

Official warnings state that the risk of serious side effects, including Cardiovascular Thrombotic Events (such as heart attack or stroke) and Gastrointestinal Events (such as bleeding), may be higher with long-term use. Official guidance notes that continuous monitoring is required due to these risks.


Q: Can Melva cause problems with sleep (insomnia or oversleeping)?

The official product information lists side effects related to the central nervous system, including dizziness and drowsiness. These reported effects may have the potential to influence a person's sleep patterns.


Q: Are there different strengths or versions of the Melva pill?

Melva is available in tablets typically in 7.5 mg and 15 mg strengths, as well as several other forms including capsules and oral suspension. It is important to know that the various oral formulations are not considered interchangeable on a milligram-for-milligram basis.


Q: Why is there specific research on Melva and women's health issues?

Regulatory documents include research summaries on how the body processes the medicine (pharmacokinetics), noting that differences have been observed between sexes. Specifically, official information indicates that advanced age and female sex are associated with a decrease in the rate the body eliminates the medicine.


Q: Is it safe to drive or operate machinery while taking Melva?

Official patient information warns that the medicine may cause effects such as dizziness, drowsiness, or blurred vision in some people. Regulatory information advises caution regarding driving or operating complex machinery.


Q: Does Melva affect appetite?

Official documentation lists gastrointestinal side effects, such as nausea and vomiting. Furthermore, signs of potential liver problems, which require attention, include loss of appetite and flu-like symptoms.


Q: What kind of monitoring (like blood tests) is sometimes needed while taking Melva?

Due to the potential for side effects on the blood (Hematologic Toxicities), official guidance emphasizes that continuous monitoring is required, including checks on blood counts (e.g., cell, platelet, and hemoglobin levels). Monitoring for signs of infection is also mandatory.


Q: Does Melva interact with herbal supplements like St. John's Wort?

Official drug labels list clinically significant interactions with medicines that affect certain liver enzymes (known as the CYP450 system). Since many herbal supplements are known to influence these same enzymes, disclosing all supplements is relevant because of the potential for interactions.


Q: Can Melva cause dizziness or lightheadedness?

Yes, official documentation lists dizziness as a known, non-serious adverse reaction associated with the use of the medicine.


Q: Is Melva a long-term treatment or short-term?

Melva is officially indicated for the relief of pain and inflammation associated with chronic conditions like Rheumatoid Arthritis and Osteoarthritis. Nevertheless, regulatory principles require the medicine to be administered at the lowest effective dose for the shortest duration necessary for the condition being treated.

How should Melva be stored and disposed of?

How to Store and Dispose of Melva

Melva (Meloxicam) must be stored and handled according to specific regulatory requirements to maintain its stability and ensure safety.

Official Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 to 25 C (68 to 77 F).
Protection Keep in a tightly closed container and a dry place; avoid excessive heat and moisture (e.g., do not store in the bathroom).
Child Safety Keep the medication out of the sight and reach of children and secure all safety caps.

Disposal Instructions

Unused or expired Meloxicam should be disposed of via a drug take-back program or by following specific guidelines for household trash disposal. The medication must not be flushed down a toilet or poured down a sink. Disposal must adhere strictly to governmental environmental and consumer safety regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Melva found in:

A-Z Index: